Literature DB >> 9861558

Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy.

E C Dompeling1, J P Donnelly, J M Raemaekers, S C Deresinski, R Feld, B E De Pauw.   

Abstract

The impact of a standardized set of diagnostic interventions on the further management of 968 episodes of fever in neutropenic cancer patients who did not respond to initial therapy was assessed prospectively. At the onset of fever, 65% of patients had no additional signs of infection, whereas skin and soft tissue infections were present in 12%, and clinical sepsis and gastrointestinal infections in 8% each. After 72 h, 41% of the fevers still remained unexplained. New foci of infection emerged in 11% of the cases involving mainly the lungs, skin and soft tissues, and urinary tract. The presence of a lower respiratory tract infection or a microbiologically defined infection of any sort was associated with higher mortality than other types of infection were. Changes in initial antibiotic therapy were based on the results of the diagnostic measures specified in the protocol in only 15% of the cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861558     DOI: 10.1007/bf02770834

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  19 in total

1.  The yield of chest radiography in febrile and neutropenic patients.

Authors:  M S Jochelson; J Altschuler; P C Stomper
Journal:  Ann Intern Med       Date:  1986-11       Impact factor: 25.391

2.  Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis.

Authors:  J E Kuhlman; E K Fishman; S S Siegelman
Journal:  Radiology       Date:  1985-12       Impact factor: 11.105

3.  Overview of empiric antibiotic therapy for the febrile neutropenic patient.

Authors:  S C Schimpff
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec

4.  Beta-lactam regimens for the febrile neutropenic patient.

Authors:  G P Bodey; V Fainstein; L S Elting; E Anaissie; K Rolston; N Khardori; H Kantarjian; C Plager; W K Murphy; F Holmes
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

5.  Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes.

Authors:  P A Pizzo; K J Robichaud; R Wesley; J R Commers
Journal:  Medicine (Baltimore)       Date:  1982-05       Impact factor: 1.889

6.  Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.

Authors: 
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

7.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.

Authors:  D Caillot; O Casasnovas; A Bernard; J F Couaillier; C Durand; B Cuisenier; E Solary; F Piard; T Petrella; A Bonnin; G Couillault; M Dumas; H Guy
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

8.  Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.

Authors:  B E De Pauw; S C Deresinski; R Feld; E F Lane-Allman; J P Donnelly
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

9.  A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.

Authors:  K V Rolston; P Berkey; G P Bodey; E J Anaissie; N M Khardori; J H Joshi; M J Keating; F A Holmes; F F Cabanillas; L Elting
Journal:  Arch Intern Med       Date:  1992-02

10.  A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients.

Authors:  V Fainstein; G P Bodey; L Elting; R Bolivar; M J Keating; K B McCredie; M Valdivieso
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.